Advanced

In vivo dopamine agonist properties of rotigotine : Role of D1 and D2 receptors

Fenu, Sandro; Espa, Elena LU ; Pisanu, Augusta and Di Chiara, Gaetano (2016) In European Journal of Pharmacology 788. p.91-183
Abstract

Rotigotine acts in vitro as a full agonist of dopamine D1 receptors at concentrations almost superimposable to those at which it acts on D2 receptors. However in vivo evidence of the differences between the agonist activity of rotigotine at D1 receptors from that on the D2 receptors has not been provided yet. In order to test the ability of rotigotine to stimulate dopamine D1 and D2 receptors in vivo, we studied the effect of SCH39166 and eticlopride, selective dopamine D1 and D2/D3 receptor antagonists respectively, on rotigotine-induced contralateral turning behavior in 6-hydroxydopamine lesioned rats. Furthermore, the expression of the immediate-early gene c-fos in the caudate-putamen, was evaluated. As a comparison, we tested the... (More)

Rotigotine acts in vitro as a full agonist of dopamine D1 receptors at concentrations almost superimposable to those at which it acts on D2 receptors. However in vivo evidence of the differences between the agonist activity of rotigotine at D1 receptors from that on the D2 receptors has not been provided yet. In order to test the ability of rotigotine to stimulate dopamine D1 and D2 receptors in vivo, we studied the effect of SCH39166 and eticlopride, selective dopamine D1 and D2/D3 receptor antagonists respectively, on rotigotine-induced contralateral turning behavior in 6-hydroxydopamine lesioned rats. Furthermore, the expression of the immediate-early gene c-fos in the caudate-putamen, was evaluated. As a comparison, we tested the D2/D3 agonist pramipexole. In primed rats, rotigotine (0.035, 0.1 and 0.35mg/kg) induced dose-dependent contralateral turning. Turning induced by 0.1mg/kg of rotigotine was reduced by pretreatment with the D1 antagonist SCH39166 and the D2 antagonist eticlopride. In drug-naive rats, rotigotine was less effective in eliciting turning but SCH39166 still reduced turning induced by rotigotine (0.35mg/kg). Pramipexole induced contralateral turning only in primed rats. SCH39166 potentiated and eticlopride abolished pramipexole-induced turning. Rotigotine induced Fos expression in the caudate-putamen and SCH39166 completely blocked it. Pramipexole failed to induce Fos. These results indicate that rotigotine acts in vivo as an agonist of D1 and D2 receptors while pramipexole is devoid of D1 activity in vivo. Given their differing DA receptor profiles, rotigotine and pramipexole might differ in their spectrum of application to the therapy of Parkinson's disease.

(Less)
Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
keywords
Animals, Behavior, Animal, Benzothiazoles, Dopamine, Dopamine Agonists, Gene Expression Regulation, Male, Oxidopamine, Proto-Oncogene Proteins c-fos, Rats, Rats, Sprague-Dawley, Receptors, Dopamine D1, Receptors, Dopamine D2, Tetrahydronaphthalenes, Thiophenes, Journal Article
in
European Journal of Pharmacology
volume
788
pages
9 pages
publisher
Elsevier
external identifiers
  • scopus:84976631066
ISSN
1879-0712
DOI
10.1016/j.ejphar.2016.06.035
language
English
LU publication?
no
id
670663ed-0e82-4341-ac27-d9c490a28c0f
date added to LUP
2017-03-29 21:39:20
date last changed
2017-04-02 04:36:27
@article{670663ed-0e82-4341-ac27-d9c490a28c0f,
  abstract     = {<p>Rotigotine acts in vitro as a full agonist of dopamine D1 receptors at concentrations almost superimposable to those at which it acts on D2 receptors. However in vivo evidence of the differences between the agonist activity of rotigotine at D1 receptors from that on the D2 receptors has not been provided yet. In order to test the ability of rotigotine to stimulate dopamine D1 and D2 receptors in vivo, we studied the effect of SCH39166 and eticlopride, selective dopamine D1 and D2/D3 receptor antagonists respectively, on rotigotine-induced contralateral turning behavior in 6-hydroxydopamine lesioned rats. Furthermore, the expression of the immediate-early gene c-fos in the caudate-putamen, was evaluated. As a comparison, we tested the D2/D3 agonist pramipexole. In primed rats, rotigotine (0.035, 0.1 and 0.35mg/kg) induced dose-dependent contralateral turning. Turning induced by 0.1mg/kg of rotigotine was reduced by pretreatment with the D1 antagonist SCH39166 and the D2 antagonist eticlopride. In drug-naive rats, rotigotine was less effective in eliciting turning but SCH39166 still reduced turning induced by rotigotine (0.35mg/kg). Pramipexole induced contralateral turning only in primed rats. SCH39166 potentiated and eticlopride abolished pramipexole-induced turning. Rotigotine induced Fos expression in the caudate-putamen and SCH39166 completely blocked it. Pramipexole failed to induce Fos. These results indicate that rotigotine acts in vivo as an agonist of D1 and D2 receptors while pramipexole is devoid of D1 activity in vivo. Given their differing DA receptor profiles, rotigotine and pramipexole might differ in their spectrum of application to the therapy of Parkinson's disease.</p>},
  author       = {Fenu, Sandro and Espa, Elena and Pisanu, Augusta and Di Chiara, Gaetano},
  issn         = {1879-0712},
  keyword      = {Animals,Behavior, Animal,Benzothiazoles,Dopamine,Dopamine Agonists,Gene Expression Regulation,Male,Oxidopamine,Proto-Oncogene Proteins c-fos,Rats,Rats, Sprague-Dawley,Receptors, Dopamine D1,Receptors, Dopamine D2,Tetrahydronaphthalenes,Thiophenes,Journal Article},
  language     = {eng},
  month        = {10},
  pages        = {91--183},
  publisher    = {Elsevier},
  series       = {European Journal of Pharmacology},
  title        = {In vivo dopamine agonist properties of rotigotine : Role of D1 and D2 receptors},
  url          = {http://dx.doi.org/10.1016/j.ejphar.2016.06.035},
  volume       = {788},
  year         = {2016},
}